ArticleScientific reports2025
Effect of miR-6767-5p on breast cancer cell phenotype and its regulatory mechanism.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The dual facets of MiRNA in modulating NF-κB in breast cancer.Cancer cell international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Objective To investigate the role and mechanism of miR-6767-5p in breast cancer (BC).
methodsWe explored the effects of miR-6767-5p on the proliferation, migration, and invasion of BC cells in vitro and in vivo through CCK-8, EdU, Transwell, and subcutaneous tumorigenesis experiments in nude mice and a tail vein lung metastasis model. Cysteine-rich intestinal protein 2 (CRIP2) was validated as a target gene of miR-6767-5p through dual-luciferase reporter assays, quantitative polymerase chain reaction (qPCR), and western blot (WB) analysis. WB was conducted to investigate the impact of miR-6767-5p on the NF-κB signaling pathway and its association with the epithelial‒mesenchymal transition (EMT). Coimmunoprecipitation, chromatin immunoprecipitation, qPCR and WB were used to verify the possible relationships among SP1, c-jun and miR-6767-5p. The relationships between miR-6767-5p and the stage and prognosis of breast cancer were investigated by in situ hybridization.
results(1) Knockdown of miR-6767-5p inhibits the proliferation, migration, and invasion of BC cell in vivo and in vitro. (2) miR-6767-5p targets CRIP2. (3) miR-6767-5p activates NF-κB and the EMT by inhibiting CRIP2. (4) miR-6767-5p can be upregulated by SP1. (5) Mitogen-activated protein kinase kinase 4 (MAP2K4) induces miR-6767-5p expression through the PI3K/AKT/c-jun/SP1 axis. (6) High expression of miR-6767-5p is associated with a poor prognosis for patients with breast cancer.
conclusions(1) miR-6767-5p is highly expressed in BC cells, stimulating their proliferation, migration, and invasion both in vivo and in vitro. (2) miR-6767-5p activates the NF-κB signaling pathway and the EMT by specifically inhibiting CRIP2. (3) The expression of miR-6767-5p is regulated by MAP2K4 through the upregulation of c-jun. (4) The expression of miR-6767-5p is positively correlated with the stage of breast cancer and a poor prognosis for patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.